Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Jan 22, 2015
Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors

Jan 20, 2015
Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

Jan 8, 2015
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

Jan 7, 2015
Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Stock Quote (NASDAQ: MACK)

Price:
9.43

Change:
- 0.13

Day High:
9.69

Day Low:
9.40

Volume:
1,312,600

4:00 PM ET on Jan 30, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools